1.a. **Full Title:** GWAS of the Ankle-brachial index

b. **Abbreviated Title (Length 26 characters):** CHARGe ABI

4. **Writing Group:** Vijay Nambi, Nora Franceschini, Aaron Folsom, Xia Li, Lynne Wagenknecht, Elizabeth Selvin, David Couper, Gerardo Heiss, Eric Boerwinkle

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. __GH__ [please confirm with your initials electronically or in writing]

**Analyst:** Xia Li

**Address:** Department of Epidemiology
University of North Carolina at Chapel Hill
137 E. Franklin St, Suite 306
Chapel Hill, NC 27514
CB#8050

Phone: (919) 966 1967  Fax: (919) 966 9800
E-mail: XiaLi@email.unc.edu

**ARIC author** to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

**Name:** Gerardo Heiss

**Address:** Department of Epidemiology, CVD Program
University of North Carolina at Chapel Hill
137 E. Franklin St, Suite 306
Chapel Hill, NC 27514

Phone: (919) 962 3253  Fax: (919) 966 9800
E-mail: gerardo_heiss@unc.edu

3. **Timeline:** Data analysis are underway following the analysis plan developed by the CHARGe working group on subclinical atherosclerosis - ABI. Meta-analyses are scheduled to begin by the end of July, conducted by the Framingham investigators who are members of this working group

4. **Rationale:**

To conduct a meta-analysis of genome-wide association study data in relation to ankle-brachial index and clinical measures of peripheral arterial disease among participants in multiple prospective cohort studies of cardiovascular disease. The collaboration is based on:
Initial in silico meta-analysis,
Reporting the evidence for association of each replicated SNP with other subclinical atherosclerotic measures (coronary, aortic, and peripheral arterial) with CIMT.
Replication in other cohorts with carotid IMT measures once results from meta-analysis are available.

5. Study Questions

Conduct a genome-wide association analysis for ABI and clinical measures of peripheral arterial disease using the set of genotyped and imputed SNPs.
   Primary analysis: Ankle brachial index
   Secondary analysis: Peripheral arterial disease, define as ABI <0.90

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

Variables (phenotype): Baseline measurements of the ankle-brachial index

Model: Linear regression for analysis of continuous variables, additive model. Analyses will be conducted either with covariates included in the model or by using unstandardized residuals. For analysis of dichotomous variables, we will use logistic regression analysis adjusted for covariates in the model.

Transform: Log transformed ABI

Covariates: Basic model: age and sex adjusted
Multivariable -- in primary analyses, restrict to "top hits": age, sex, cigarette smoking (current, former, never), BMI, dichotomous hypertension (defined by SBP, DBP and treatment status), total cholesterol, HDL cholesterol, lipid lowering therapy, DM, triglycerides.

Subgroups: In secondary analyses, age specific (< 55 and > 55), sex-specific

Exclusions: ABI >= 1.4

Control for multiple comparisons: 1 EFP; i.e., p< 1/# tests

Imputation: Imputation into HapMap 2.5 million SNPs

Meta-analysis: Meta-analysis centralized

7.a. Will the data be used for non-CVD analysis in this manuscript? ____ Yes  ____X__ No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = “CVD Research” for non-DNA analysis, and for DNA analysis RES_DNA = “CVD Research” would be used? ____ Yes  ____ No
8.a. Will the DNA data be used in this manuscript?  

__X__ Yes    ____ No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = “No use/storage DNA”?

__X__ Yes    ____ No

8.c. If yes, is the author aware that the participants with RES_DNA = ‘not for profit’ restriction must be excluded if the data are used by a for profit group?

__X__ Yes    ____ No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://www.cscc.unc.edu/ARIC/search.php

__X__  Yes    ______ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

No overlapping manuscripts were identified

11. a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?

_____ Yes    __X__ No

11.b. If yes, is the proposal

__X__ A. primarily the result of an ancillary study (list number* __2004,11)

___ B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* __________ __________ __________)

*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.